Supplement to

The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial

Content

Investigators in the ATTRACT trial	1
Inclusion and Exclusion Criteria in the ATTRACT trial	2
Withdrawal Criteria in the ATTRACT trial	3
Endpoints in the ATTRACT trial	3
Table E1. Effect on biomarkers	4
Table E2. Need for supplemental oxygen therapy	5
Table E3. Treatment-Emergent Adverse Events by MedDRA System Organ Class	5

Investigators in the ATTRACT trial

Coordinating Investigator	
Professor Joanna Porter	Department of Thoracic Medicine, University College London Hospital NHS
	Trust, London NW1 2PG, England & UCL Respiratory
Principle Investigators	Investigatory Site
Dr Reema Kashiva	Department of Medicine, Noble Hospitals Pvt. Ltd, 153 Magarpatta City Road,
	Hadapsar, Pune, Maharashtra, India 411013
Dr Chirag Chhatwani	Infectious Disease, Metas Adventist Hospital, 13-B, Ninth No 0363 to 0365,
	RS No 21, Opp. Chowpati Main Road, Athwalines, Surat, Gujarat, India
	395001
Dr Atul Rajkondawar	Department of Medicine, Government Medical College and Hospital, Hanuman
	Nagar, Ajni Rd, Medical Chowk, Ajni, Nagpur, Maharashtra, India 440003
Dr Paritosh Baghel	Internal Medicine S.L. Raheja Hospital Raheja Rugnalaya Marg, Mahim (W),
	Mumbai, Maharashtra. India 400016
Dr Kartikeya Parmar	Medicine Department, Civil Hospital and B J Medical College, Asarwa,
	Ahmedabad, Gujarat, India 380016
Dr Kapil Zirpe	"Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, 40 Sasoon
	Rd, Sangamvadi, Pune, Maharashtra, India 411001
Dr. Mahesh Sutariya	Critical Care Medicine, Unity Trauma Center and ICU (Unity
	Hospital) Nr. D.R. World, Opp Raghuvir Business Empire, Aai Mata Rd,
	Parvat Patiya, Surat, Gujarat, India 395010
Dr Nirav Bhalani	Clinical Research Department, Near Siddharth Bunglows, Sama-Savli Road,
	Vadodara, Gujarat, India 390022

Inclusion and Exclusion Criteria in the ATTRACT trial

Inclusion Criteria

- 1) Written informed consent, consistent with ICH GCP R2 and local laws, obtained before the initiation of any trial related procedure
- 2) Diagnosis of coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test < 4 days before Visit 1 with signs of an acute respiratory infection
- 3) Age > 18 and < 70 years
- 4) CRP > 50 and < 150 mg/l
- 5) Admitted to a hospital or controlled facility (home quarantine is not sufficient)
- 6) In the opinion of the Investigator, the subject will be able to comply with the requirements of the protocol

Exclusion Criteria

- 1) Any previous experimental treatment for COVID-19
- 2) Need for mechanical invasive or non-invasive ventilation
- 3) Concurrent respiratory disease such as chronic obstructive pulmonary disease, idiopathic pulmonary disease (IPF) and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis
- 4) Participation in any other interventional trial within 3 months prior to Visit 1
- 5) Any of the following findings at Visit 1:
 - Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb) or human immunodeficiency virus 1+2 antigen/antibody (HIV 1+2 Ag/Ab)
 - Positive pregnancy test (see Section 8.2.3)
- 6) Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the investigator
- 7) Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions (e.g. contraindications to cataract surgery), which in the opinion of the Investigator makes the subject inappropriate for this trial
- 8) Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I
- 9) Treatment with any of the medications listed below within 1 week prior to Visit 1:
 - Strong Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's Wort, phenobarbital, rifabutin, carbamazepine, anti HIV drugs, barbiturates)
 - Warfarin
- 10) Pregnant or breast-feeding female subjects
- 11) Female subjects of childbearing potential not willing to use contraceptive methods as described in Section 5.3.1
- 12) Male subjects not willing to use contraceptive methods as described in Section 5.3.1
- 13) Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)

Withdrawal Criteria in the ATTRACT trial

A subject will be withdrawn from IMP if any of the following occurs:

- Need for mechanical invasive or non-invasive ventilation
- Discharge from the hospital/controlled facility
- Major protocol deviations as defined by Sponsor.
- Sponsor decision to stop the trial or to stop the subject's participation in the trial; reasons may include medical, safety, or regulatory issues, or other reasons consistent with applicable laws, regulations, and GCP
- It is the wish of the subject for any reason
- The Investigator judges it necessary due to medical reasons
- Adverse events such as:
 - Serious cardiovascular complications such as severe peripheral oedema or significant bradycardia indicating a potential risk for the subject as evaluated by the Investigator
 - Moderate to severe skin rashes as judged by the Investigator e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis
- Pregnancy

Withdrawal from trial:

- Enrolment in other clinical studies involving investigational products or enrolment in other types of clinical research judged not to be scientifically or medically compatible with this trial.
- Disallowed treatment during the trial period
- It is the wish of the subject for any reason
- The Investigator judges it necessary due to medical reasons
- Adverse events
- Lost to follow-up

Endpoints in the ATTRACT trial

Primary endpoint

Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)

Secondary endpoints

- 1) Change from baseline in:
 - Body temperature
 - IL-6
 - IL-10
 - TNF
 - CA125
 - Ferritin
- 2) Number of subjects not in need of oxygen supply
- 3) Number of subjects not in need of mechanical invasive or non-invasive ventilation
- 4) Time to need of mechanical invasive or non-invasive ventilation
- 5) Time on oxygen supply (for those not needing mechanical invasive or non-invasive ventilation
- 6) Adverse events

Exploratory endpoints

Blood samples will be saved for potential future analyses of biomarkers reflecting inflammation and lung injury

Table E1. Effect on biomarkers

Biomarker	C21	Placebo	Treatment
	(N=51)	(N=55)	Ratio
CRP - all patients (mg/L)			
Screening	86.0 (30.2)	80.1 (26.5)	
Baseline	49.8 (38.7)	61.5 (47.6)	
End of treatment	13.2 (14.7)	23.9 (35.6)	
Adjusted treatment geometric mean baseline ratio	0.19	0.22	0.85 (p=0.489)
CRP - patients with O ₂ treatment at baseline (mg/L)			
Baseline	41.4 (31.9)	65.1 (51.4)	
End of treatment	12.5 (13.3)	25.4 (37.3)	
Adjusted treatment geometric mean baseline ratio	0.16	0.28	0.59 (p=0.088)
Interleukin 10 (pg/mL)			
Baseline	8.41 (8.90)	10.06 (12.81)	
End of treatment	13.12 (35.51)	8.08 (12.48)	
Adjusted treatment geometric mean baseline ratio	0.66	0.73	0.90 (p=0.535)
Interleukin 6 (pg/mL)			
Baseline	51.13 (114.41)	34.85 (39.79)	
End of treatment	59.39 (155.97)	27.83 (60.95)	
Adjusted treatment geometric mean baseline ratio	0.73	0.73	1.00 (p=0.992)
Tumor Necrosis Factor (pg/mL)			
Baseline	17.02 (18.70)	18.29 (16.65)	
End of treatment	24.53 (56.21)	23.86 (46.59)	
Adjusted treatment geometric mean baseline ratio	0.91	1.01	0.90 (p=0.474)
CA125 (μ/mL)			
Baseline	14.28 (12.88)	20.46 (38.78)	
End of treatment	16.58 (10.86)	19.72 (18.49)	
Adjusted treatment geometric mean baseline ratio	1.16	1.17	0.99 (p=0.942)
Ferritin (ng/mL)			
Baseline	464.2 (324.6)	707.5 (564.3)	
End of treatment	411.6 (331.3)	549.4 (550.6)	
Adjusted treatment geometric mean baseline ratio	0.75	0.74	1.00 (p=0.973)

Values are Mean (SD) unless otherwise specified.

Table E2. Need for supplemental oxygen therapy

Biomarker	C21	Placebo	p-value
	(N=51)	(N=55)	
All subjects (C21 N=51, Placebo N=55)			
Oxygen therapy at end of treatment, N (%)	14 (27.5)	25 (45.5)	0.055
Oxygen therapy at Day 14, N (%)	1 (2.0)	11 (20.0)	0.003
Days on oxygen up to Day 14, N (%)	259 (36.3)	353 (45.8)	0.190
Subjects on oxygen at baseline (C21 N=37, Placebo N=39)			
Oxygen therapy at end of treatment, N (%)	14 (37.8)	23 (59.0)	0.065
Oxygen therapy at Day 14, N (%)	1 (2.7)	10 (25.6)	0.004
Days on oxygen up to Day 14, N (%)	247 (47.7)	323 (59.2)	0.101
Subjects not on oxygen at baseline (C21 N=14, Placebo N=16)			
Oxygen therapy at end of treatment, N (%)	0 (0.0)	2 (12.5)	0.171
Oxygen therapy at Day 14, N (%)	0 (0.0)	1 (1.8)	0.341
Days on oxygen up to Day 14, N (%)	12 (6.1)	30 (13.4)	0.695

Table E3. Treatment-Emergent Adverse Events by MedDRA System Organ Class

System organ class	C21	Placebo
Preferred term	(N=51)	(N=55)
Metabolism and nutrition disorders	19 (23.5)	12 (18.2)
Hyperglycemia	14 (21.6)	5 (7.3)
Hyponatremia	2 (3.9)	3 (5.5)
Dyslipidemia	1 (2.0)	2 (3.6)
Gastrointestinal disorders	4 (7.8)	6 (10.9)
Constipation	0 (0.0)	4 (7.3)
Renal and urinary disorders	1 (2.0)	4 (7.3)
Glycosuria	1 (2.0)	3 (5.5)

Table includes Adverse Events reported by >2 subject
Data presented as number of events (% of subjects)